Sandeepa Sur1, Zixuan Lin1, Yang Li1, Sevil Yasar1, Paul Rosenberg1, Abhay Moghekar1, Xirui Hou1, Rita Kalyani1, Kaisha Hazel1, George Pottanat1, Cuimei Xu1, Peter van Zijl1, Jay Pillai1, Peiying Liu1, Marilyn Albert1, Hanzhang Lu2. 1. From the Departments of Radiology (S.S., Z.L., Y.L., X.H., K.H., G.P., C.X., P.v.Z., J.P., P.L., H.L.), Biomedical Engineering (Z.L., X.H., H.L.), Medicine (S.Y., R.K.), Psychiatry and Behavioral Sciences (P.R.), Neurology (A.M., M.A.), and Neurosurgery (J.P.), Johns Hopkins University, School of Medicine; and F.M. Kirby Research Center (P.v.Z., H.L.), Kennedy Krieger Institute, Baltimore, MD. 2. From the Departments of Radiology (S.S., Z.L., Y.L., X.H., K.H., G.P., C.X., P.v.Z., J.P., P.L., H.L.), Biomedical Engineering (Z.L., X.H., H.L.), Medicine (S.Y., R.K.), Psychiatry and Behavioral Sciences (P.R.), Neurology (A.M., M.A.), and Neurosurgery (J.P.), Johns Hopkins University, School of Medicine; and F.M. Kirby Research Center (P.v.Z., H.L.), Kennedy Krieger Institute, Baltimore, MD. hanzhang.lu@jhu.edu.
Abstract
OBJECTIVE: To determine whether MRI-based cerebrovascular reactivity (CVR) can predict cognitive performance independently of Alzheimer pathologic markers, we studied the relationship between cognition, CVR, and CSF-derived β-amyloid42 (Aβ42) and tau in a group of elderly individuals with mixed Alzheimer and vascular cognitive impairment and dementia. METHODS: This was a cross-sectional study of 72 participants 69 ± 8 years of age consisting of individuals with normal cognition (n = 28) and cognitive impairment (n = 44) (including 36 with mild cognitive impairment [MCI] and 8 with mild dementia). CVR was measured with hypercapnia-MRI. Whole-brain CVR (percent blood oxygen level-dependent per 1 mm Hg Etco2) was used to estimate vasodilatory capacity. Montreal Cognitive Assessment (MoCA) scores, cognitive domains scores, and a global composite cognitive score were obtained. AD biomarkers included CSF assays of Aβ42 and tau. RESULTS: Whole-brain CVR was lower in the impaired (mean ± SE, 0.132 ± 0.006%/mm Hg) compared to the normal (0.151 ± 0.007%/mm Hg) group (β = -0.02%/mm Hg; 95% confidence interval [CI] -0.038 to -0.001). After adjustment for CSF Aβ42 and tau, higher whole-brain CVR was associated with better performance on the MoCA (β = 29.64, 95% CI 9.94-49.34) and with a global composite cognitive score (β = 4.32, 95% CI 0.05-8.58). When the CVR marker was compared with the Fazekas score based on white matter hyperintensities and vascular risk-score in a single regression model predicting the MoCA score, only CVR revealed a significant effect (β = 28.09, 95% CI 6.14-50.04), while the other 2 measures were not significant. CONCLUSIONS: CVR was significantly associated with cognitive performance independently of AD pathology. Whole-brain CVR may be a useful biomarker for evaluating cognitive impairment related to vascular disease in older individuals. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CVR was significantly associated with cognitive performance independent of AD pathology.
OBJECTIVE: To determine whether MRI-based cerebrovascular reactivity (CVR) can predict cognitive performance independently of Alzheimer pathologic markers, we studied the relationship between cognition, CVR, and CSF-derived β-amyloid42 (Aβ42) and tau in a group of elderly individuals with mixed Alzheimer and vascular cognitive impairment and dementia. METHODS: This was a cross-sectional study of 72 participants 69 ± 8 years of age consisting of individuals with normal cognition (n = 28) and cognitive impairment (n = 44) (including 36 with mild cognitive impairment [MCI] and 8 with mild dementia). CVR was measured with hypercapnia-MRI. Whole-brain CVR (percent blood oxygen level-dependent per 1 mm Hg Etco2) was used to estimate vasodilatory capacity. Montreal Cognitive Assessment (MoCA) scores, cognitive domains scores, and a global composite cognitive score were obtained. AD biomarkers included CSF assays of Aβ42 and tau. RESULTS: Whole-brain CVR was lower in the impaired (mean ± SE, 0.132 ± 0.006%/mm Hg) compared to the normal (0.151 ± 0.007%/mm Hg) group (β = -0.02%/mm Hg; 95% confidence interval [CI] -0.038 to -0.001). After adjustment for CSF Aβ42 and tau, higher whole-brain CVR was associated with better performance on the MoCA (β = 29.64, 95% CI 9.94-49.34) and with a global composite cognitive score (β = 4.32, 95% CI 0.05-8.58). When the CVR marker was compared with the Fazekas score based on white matter hyperintensities and vascular risk-score in a single regression model predicting the MoCA score, only CVR revealed a significant effect (β = 28.09, 95% CI 6.14-50.04), while the other 2 measures were not significant. CONCLUSIONS: CVR was significantly associated with cognitive performance independently of AD pathology. Whole-brain CVR may be a useful biomarker for evaluating cognitive impairment related to vascular disease in older individuals. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CVR was significantly associated with cognitive performance independent of AD pathology.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: David S Knopman; Michael E Griswold; Seth T Lirette; Rebecca F Gottesman; Kejal Kantarci; A Richey Sharrett; Clifford R Jack; Jonathan Graff-Radford; Andrea L C Schneider; B Gwen Windham; Laura H Coker; Marilyn S Albert; Thomas H Mosley Journal: Stroke Date: 2015-01-06 Impact factor: 7.914
Authors: Gustavo C Román; Perminder Sachdev; Donald R Royall; Roger A Bullock; Jean-Marc Orgogozo; Secundino López-Pousa; Raul Arizaga; Anders Wallin Journal: J Neurol Sci Date: 2004-11-15 Impact factor: 3.181
Authors: Kelly Davis Garrett; Jeffrey N Browndyke; William Whelihan; Robert H Paul; Margaret DiCarlo; David J Moser; Ronald A Cohen; Brian R Ott Journal: Arch Clin Neuropsychol Date: 2004-09 Impact factor: 2.813
Authors: Michal S Beeri; Hung-Mo Lin; Mary Sano; Ramit Ravona-Springer; Xiaoyu Liu; Barbara B Bendlin; Carey E Gleason; Elizabeth Guerrero-Berroa; Laili Soleimani; Lenore J Launer; Scott Ehrenberg; Orit Lache; Yaakov K Seligman; Andrew P Levy Journal: JAMA Netw Open Date: 2018-11-02
Authors: Claire E Sexton; Kaarin J Anstey; Filippo Baldacci; C J Barnum; Anna M Barron; Kaj Blennow; Henry Brodaty; Samantha Burnham; Fanny M Elahi; Jürgen Götz; Yun-Hee Jeon; Maya Koronyo-Hamaoui; Susan M Landau; Nicola T Lautenschlager; Simon M Laws; Darren M Lipnicki; Hanzhang Lu; Colin L Masters; Wendy Moyle; Akinori Nakamura; Giulio Maria Pasinetti; Naren Rao; Christopher Rowe; Perminder S Sachdev; Peter R Schofield; Einar M Sigurdsson; Kate Smith; Velandai Srikanth; Cassandra Szoeke; Malú G Tansey; Rachel Whitmer; Donna Wilcock; Tien Y Wong; Lisa J Bain; Maria C Carrillo Journal: Alzheimers Dement Date: 2021-05-31 Impact factor: 16.655
Authors: Claire V Burley; Susan T Francis; Kate N Thomas; Anna C Whittaker; Samuel J E Lucas; Karen J Mullinger Journal: Front Physiol Date: 2021-04-12 Impact factor: 4.566
Authors: Peiying Liu; Dengrong Jiang; Marilyn Albert; Christopher E Bauer; Arvind Caprihan; Brian T Gold; Steven M Greenberg; Karl G Helmer; Kay Jann; Gregory Jicha; Pavel Rodriguez; Claudia L Satizabal; Sudha Seshadri; Herpreet Singh; Jeffrey F Thompson; Danny J J Wang; Hanzhang Lu Journal: Neuroimage Date: 2021-11-23 Impact factor: 7.400
Authors: Andrew E Beaudin; Cheryl R McCreary; Erin L Mazerolle; Myrlene Gee; Breni Sharma; Arsenije Subotic; Angela M Zwiers; Emily Cox; Krista Nelles; Anna Charlton; Richard Frayne; Zahinoor Ismail; Christian Beaulieu; Glen C Jickling; Richard M Camicioli; G Bruce Pike; Eric E Smith Journal: Neurology Date: 2022-02-24 Impact factor: 11.800